Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$23.89 -2.5%	$23.94	$20.92 ▼ $42.48	$45.26B	N/A	261,218 shs	362,306 shs
IPSEY IPSEN	$34.03 -1.7%	$31.48	$25.11 ▼ $34.61	$11.41B	0.49	764 shs	3,726 shs
ONC BeOne Medicines	$306.05 +2.7%	$285.26	$170.99 ▼ $330.63	$33.54B	0.21	328,635 shs	360,221 shs
SDZNY Sandoz Group	$62.89 -0.2%	$57.97	$35.61 ▼ $63.72	$27.67B	0.6	22,405 shs	32,820 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	0.00%	-6.24%	-3.00%	-12.17%	-42.94%
IPSEY IPSEN	0.00%	-0.18%	+5.62%	+13.02%	+13.89%
ONC BeOne Medicines	0.00%	-2.43%	+2.35%	+24.45%	+30,604,999,900.00%
SDZNY Sandoz Group	0.00%	+0.18%	+10.35%	+22.47%	+42.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IPSEY IPSEN	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	0.6465 of 5 stars	1.5	0.0	0.0	0.0	2.6	1.7	0.6
SDZNY Sandoz Group	2.126 of 5 stars	0.0	5.0	0.8	0.0	2.4	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
IPSEY IPSEN	3.00	Buy	N/A	N/A
ONC BeOne Medicines	3.00	Buy	$330.89	8.12% Upside
SDZNY Sandoz Group	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest IPSEY, DSNKY, ONC, and SDZNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	SDZNY Sandoz Group	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/7/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$349.00 ➝ $364.00
8/7/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$350.00 ➝ $365.00
7/17/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$321.00 ➝ $345.00
7/16/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$311.00 ➝ $349.00
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00
6/6/2025	DSNKY Daiichi Sankyo	Nomura Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSNKY Daiichi Sankyo	$12.39B	3.65	$1.26 per share	19.03	$5.61 per share	4.26
IPSEY IPSEN	$3.87B	2.95	N/A	N/A	N/A	∞
ONC BeOne Medicines	$4.56B	7.35	N/A	N/A	$34.10 per share	8.98
SDZNY Sandoz Group	$10.36B	2.67	$2.67 per share	23.53	$18.56 per share	3.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSNKY Daiichi Sankyo	$1.95B	$1.03	23.19	21.92	1.18	15.65%	17.92%	8.61%	10/30/2025 (Estimated)
IPSEY IPSEN	$374.30M	N/A	0.00	11.82	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	-$644.79M	-$1.73	N/A	431.06	N/A	-3.89%	-1.22%	-0.72%	N/A
SDZNY Sandoz Group	$1M	N/A	0.00	18.94	1.06	N/A	N/A	N/A	N/A

Latest IPSEY, DSNKY, ONC, and SDZNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	ONC BeOne Medicines	$0.48	$0.84	+$0.36	$0.84	$1.24 billion	$1.32 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSNKY Daiichi Sankyo	$0.29	1.21%	N/A	28.16%	N/A
IPSEY IPSEN	$0.26	0.76%	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
SDZNY Sandoz Group	$0.43	0.68%	N/A	N/A	N/A

Latest IPSEY, DSNKY, ONC, and SDZNY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/3/2025	IPSEY IPSEN		$0.2896	0.97%	6/9/2025	6/10/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSNKY Daiichi Sankyo	0.06	2.53	1.85
IPSEY IPSEN	N/A	1.34	1.15
ONC BeOne Medicines	0.04	1.95	1.72
SDZNY Sandoz Group	0.57	1.24	0.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSNKY Daiichi Sankyo	N/A
IPSEY IPSEN	N/A
ONC BeOne Medicines	48.55%
SDZNY Sandoz Group	0.06%

Insider Ownership

Company	Insider Ownership
DSNKY Daiichi Sankyo	N/A
IPSEY IPSEN	N/A
ONC BeOne Medicines	6.62%
SDZNY Sandoz Group	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
IPSEY IPSEN	5,358	335.26 million	N/A	Not Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
SDZNY Sandoz Group	23,406	440.00 million	N/A	Not Optionable

IPSEY, DSNKY, ONC, and SDZNY Headlines

Recent News About These Companies

Sandoz Group (OTCMKTS:SDZNY) Sets New 1-Year High - Time to Buy?

August 31 at 10:34 AM | marketbeat.com

Sandoz Group (OTCMKTS:SDZNY) Trading 1.6% Higher - Time to Buy?

August 30 at 3:30 AM | marketbeat.com

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

August 27, 2025 | zacks.com

Kepler Capital Remains a Buy on Sandoz Group Ltd (SDZXF)

August 17, 2025 | theglobeandmail.com

Sandoz Group: Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

August 12, 2025 | finanznachrichten.de

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

August 12, 2025 | globenewswire.com

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

August 11, 2025 | zacks.com

Sandoz Group Ltd’s Strategic Growth Amid Market Challenges

August 9, 2025 | theglobeandmail.com

Sandoz Group (OTCMKTS:SDZNY) Hits New 52-Week High - Here's What Happened

August 8, 2025 | marketbeat.com

Sandoz Group AG (SDZNY) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

August 7, 2025 | globenewswire.com

Sandoz Group (OTCMKTS:SDZNY) Shares Down 0.9% - Time to Sell?

August 6, 2025 | marketbeat.com

Sandoz targets 70% price cut for weight-loss drugs in Canada, FT reports

August 4, 2025 | reuters.com

Sandoz to acquire Just-Evotec Biologics from Evotec for $300M

July 30, 2025 | msn.com

Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site

July 30, 2025 | pharmiweb.comP

Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site

July 30, 2025 | pharmiweb.comP

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site

July 30, 2025 | accessnewswire.comA

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

July 30, 2025 | accessnewswire.comA

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

July 30, 2025 | globenewswire.com

Sandoz Group AG (SDZNY) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

SDZNY - Sandoz Group AG ADR Dividends - Morningstar

July 1, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPSEY, DSNKY, ONC, and SDZNY Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

$23.89 -0.61 (-2.49%)

As of 08/29/2025 03:59 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

IPSEN OTCMKTS:IPSEY

$34.03 -0.58 (-1.68%)

As of 08/29/2025 02:16 PM Eastern

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

BeOne Medicines NASDAQ:ONC

$306.05 +8.09 (+2.72%)

As of 08/29/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Sandoz Group OTCMKTS:SDZNY

$62.89 -0.11 (-0.17%)

As of 08/29/2025 03:58 PM Eastern

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time